Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Immutep De nieuwe australische Galapagos ??

BioPharma« Terug naar discussie overzicht

Immutep De nieuwe australische Galapagos ??

Volgen
582 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 30 »» | Laatste | Omlaag ↓
  2. frederic_knight 23 januari 2021 23:57
    Immutep (NASDAQ:IMMP) drops 6% in premarket after its licensing partners, GlaxoSmithKline (NYSE:GSK), has decided to discontinue its Phase 2 trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, derived from Immutep’s IMP731 antibody, in patients with active ulcerative colitis. The decision is based on the assessment of clinical data as part of a planned interim analysis. GSK is conducting further reporting, assessment and analyses of the efficacy and safety data to determine next steps for the GSK2831781 development program.
    The company’s collaboration with GSK remains in place and GSK2831781 continues to be under an exclusive license with GSK, which has also been explored in another autoimmune disease.
    Under the terms of its ongoing collaboration agreement with GSK, Immutep is eligible to receive up to a total of £54M in remaining developmental milestone payments as well as single-digit tiered royalties, if GSK2831781 is commercialized. GSK is responsible for all costs associated with the clinical development and commercialization of GSK2831781.
    Additionally, the company announced operational and financial position, with $54.9M in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022.
    Th Company has also announced its intention to run a new randomized, controlled Phase 2 study in ~160 1st line head and neck squamous cell carcinoma patients which is a more commercially relevant indication. Further details will be announced in due course.

    Bron:
    seekingalpha.com/news/3653491-gsk-pul...
  4. [verwijderd] 25 januari 2021 15:14
    klopt, met GSK hebben ze nog 2 studies lopen, o.a. Psoriasis

    koersreactie vrijdag gelukkig beperkt, komt ook omdat het een bedrijf is met een brede pijplijn denk ik... niet alles kan goed gaan....
    goede financiële basis, hoop mooie dingen in het vooruitzicht... ik hou vast en breid uit waar mogelijk ;-)

    Bijlage:
  9. [verwijderd] 26 januari 2021 23:50
    MMUTEP ANNOUNCES ADVANCEMENT OF PHASE II TRIAL FOR EFTILAGIMOD ALPHA IN COVID-
    19 PATIENTS TO RANDOMISED PORTION OF THE STUDY
    • Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the
    randomised portion of the Phase II EAT COVID study
    • Up to 110 COVID-19 patients to participate in investigator-initiated study at the University Hospital
    Pilsen, Czech Republic
  10. Mr. T 27 januari 2021 05:33
    Kan iemand meer duiding geven over Immutep op 12 januari 2021. Als ik op Yahoo kijk en ik zet de grafiek op 6 maand dan is er 1 hoge piek te zien. Als ik kijk naar '52 week range' zou hij de 45 AUD hebben aangetikt. Heeft er iemand die dag belachelijk veel geld verdiend of zie ik iets over het hoofd?
  14. Maisha marefu 27 januari 2021 10:29
    Van de site van immutep.

    Following this data review, the DSMB recommended that the study advance
    with enrolment for the randomised portion of the study. All six patients (age range, 50-83 years; 2 women)
    received the three planned 10 mg efti injections and have since been discharged from hospital. No adverse events have been reported.

    Professor Matejovic, Principal Investigator for the study, stated, “Sadly, hospitals and doctors in the Czech Republic are increasingly overwhelmed and are facing severe challenges treating the high volume of patients
    with COVID-19. Despite this, the DSMB has prioritized the review of the safety data for the first six patients
    in the EAT COVID Phase II study. We are pleased with their recommendation to continue the trial and move
    ahead with the randomised, placebo-controlled portion of the study.”
  17. frederic_knight 27 januari 2021 16:24
    Immutep's lead candidate efti moves forward in mid-stage COVID-19 study
    Jan. 27, 2021 9:20 AM ET

    Immutep's (NASDAQ:IMMP) gains 6% in premarket, after independent Data and Safety Monitoring Board (DSMB) has recommended Phase 2 study evaluating company's lead product candidate eftilagimod alpha (efti) in COVID-19, to advance with enrollment for the randomized portion of the study.
    The recommendation, comes after completion of a safety run-in data of the first six patients in Phase 2 trial, who received the three planned 10 mg efti injections and have since been discharged from hospital. No adverse events have been reported.
    Up to 110 COVID-19 patients will participate in investigator-initiated study at the University Hospital Pilsen, Czech Republic.
582 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 30 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
B&S Group SA 4,395 +0,34 +8,25%
Galapagos 25,380 +1,42 +5,93%
EBUSCO HOLDING 0,925 +0,05 +5,16%
ALLFUNDS GROUP 5,430 +0,27 +5,13%
BESI 112,800 +5,30 +4,93%
THEON INTERNAT 10,340 +0,48 +4,87%
RENEWI 7,150 +0,24 +3,47%
UNILEVER PLC 56,440 +1,88 +3,45%
RELX 44,820 +1,42 +3,27%
FASTNED 21,300 +0,65 +3,15%
Pharming 0,716 +0,02 +3,02%
Wolters Kluwer 157,950 +4,60 +3,00%
WDP 20,720 +0,60 +2,98%
UMG 22,580 +0,63 +2,87%
CTP 15,100 +0,40 +2,72%
DSM FIRMENICH AG 107,250 +2,40 +2,29%
INPOST 17,210 +0,35 +2,08%
SIGNIFY NV 21,740 +0,44 +2,07%
IMCD 140,150 +2,80 +2,04%
Eurocommercial Properties 23,300 +0,45 +1,97%
Fagron 18,620 +0,34 +1,86%
ADYEN NV 1.290,400 +23,40 +1,85%
ASML 642,100 +10,60 +1,68%
ASMI 504,600 +8,20 +1,65%
Ahold Delhaize 32,830 +0,52 +1,61%
AEX 879,80 +13,67 +1,58%
Kendrion 10,900 +0,16 +1,49%
JDE PEET'S 18,600 +0,23 +1,25%
OCI 11,315 +0,13 +1,16%
Heineken 70,640 +0,76 +1,09%
ACOMO 17,640 +0,18 +1,03%
Sif Holding 12,220 +0,12 +0,99%
AMX 866,26 +8,37 +0,98%
NX FILTRATION 4,240 +0,04 +0,95%
Avantium 2,170 +0,02 +0,93%
EXOR NV 95,200 +0,85 +0,90%
Brunel 8,470 +0,07 +0,83%
ASCX 1.183,15 +9,48 +0,81%
RANDSTAD NV 40,610 +0,31 +0,77%
Nedap N.V. 52,400 +0,40 +0,77%
Philips Koninklijke 25,220 +0,19 +0,76%
Sligro 10,660 +0,08 +0,76%
Corbion 21,980 +0,16 +0,73%
Arcadis 62,200 +0,45 +0,73%
AALBERTS NV 34,100 +0,22 +0,65%
ASR Nederland 45,130 +0,29 +0,65%
Vastned 24,250 +0,15 +0,62%
Wereldhave 14,120 +0,08 +0,57%
KPN 3,620 +0,02 +0,56%
Aegon 5,960 +0,03 +0,51%
TomTom 5,200 +0,03 +0,48%
Akzo Nobel 55,880 +0,26 +0,47%
ArcelorMittal 23,990 +0,08 +0,33%
SHELL PLC 31,610 +0,09 +0,27%
NSI 19,700 +0,04 +0,20%
Accsys 0,555 +0,00 +0,18%
HEIJMANS KON 27,950 +0,05 +0,18%
Fugro 16,900 +0,03 +0,18%
AMG Critical Materials N.V. 14,980 +0,01 +0,07%
PostNL 1,009 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO (RIGHT) 0,000 -0,16 -99,81%
SBM Offshore 17,720 -0,30 -1,66%
CM.COM 6,000 -0,10 -1,64%
JUST EAT TAKEAWAY 14,010 -0,23 -1,58%
Alfen N.V. 11,245 -0,17 -1,45%
Vopak 45,100 -0,60 -1,31%
Flow Traders 21,380 -0,28 -1,29%
BAM 4,010 -0,05 -1,23%
ING 14,652 -0,17 -1,16%
ForFarmers 3,280 -0,03 -0,91%
Van Lanschot Kempen NV 43,100 -0,35 -0,81%
ABN AMRO BANK N.V. 14,735 -0,12 -0,77%
AZERION 1,266 -0,01 -0,63%
Air France-KLM 7,358 -0,05 -0,62%
TKH 31,720 -0,18 -0,56%
NN Group 44,640 -0,20 -0,45%
Basic-Fit 21,500 -0,08 -0,37%
PROSUS 37,970 -0,13 -0,35%
Aperam 27,560 -0,06 -0,22%
vlag naam koers verschil relatief verschil
AEX 879,80 +13,67 +1,58%
AEX GR 3.450,86 +53,61 +1,58%
Germany40^ 19.354,60 +208,43 +1,09%
FTSE 100 8.262,08 +112,81 +1,38%
EURO50 4.797,55 0,00 0,00%
US30^ 44.302,90 0,00 0,00%
Nasd100^ 20.778,50 0,00 0,00%
US500^ 5.965,55 0,00 0,00%
Japan225^ 38.598,50 0,00 0,00%
VD-NEW 16,06 -0,99 -5,82%
#/^ Index indications calculated real time, zie disclaimer